Expertise in
12
conditions

Dr. Mukul R. Gupta

Oncology
540 West Pueblo Street, 
Santa Barbara, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
12
conditions
540 West Pueblo Street, 
Santa Barbara, CA 

Overview

Mukul Gupta is an Oncologist practicing medicine in Santa Barbara, California.

Dr. Gupta is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Familial Pancreatic Cancer, Myelodysplastic Syndrome (MDS), Urothelial Cancer, Colorectal Cancer, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 6 clinical trials. Dr. Gupta is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CA

Fellowships

LAC Los Angeles County+USC Medical Center

Hospital Affiliations

Santa Barbara Cottage Hospital
Santa Ynez Valley Cottage Hospital
Goleta Valley Cottage Hospital
Marian Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Ridley-Tree Cancer Center
540 West Pueblo Street, Santa Barbara, CA 93105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drug: ARX788
Study Phase: Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination With Ramucirumab and Paclitaxel in Patients With HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With Tucatinib in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination With Ramucirumab and Paclitaxel in Patients With HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With Tucatinib in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2022
Intervention Type: Drug
Study Drugs: Cinrebafusp alfa, Ramucirumab, Paclitaxel, Tucatinib
Study Phase: Phase 2
View 5 Less Clinical Trials

5 Total Publications

Engineering Hetero-Layered Mannodendrimers to Enhance Macrophage Receptor Binding.
Engineering Hetero-Layered Mannodendrimers to Enhance Macrophage Receptor Binding.
Journal: Biomacromolecules
Published: October 28, 2025
Similar Doctors
Expertise in
35
conditions
Expertise in
35
conditions
Referral may be required

Steven Zelko

309 W Quinto St, 
Santa Barbara, CA 
 (0.3 miles away)
805-563-0041
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Greenwald is an Oncologist practicing medicine in Santa Barbara, California. Dr. Greenwald is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Severe Congenital Neutropenia, Chronic Familial Neutropenia, Non-Hodgkin Lymphoma, and Familial Colorectal Cancer.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Office

111 E Victoria St, 
Santa Barbara, CA 
 (1.1 miles away)
805-563-0041
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Juliet Penn is an Oncologist practicing medicine in Santa Barbara, California. Dr. Penn is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Paget Disease of the Breast, Angiosarcoma, and Bone Marrow Aspiration.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

W Michael Hogan MD PC

2900 Loma Vista Rd Ste 205, 
Ventura, CA 
 (30.3 miles away)
805-642-4830
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Hogan is an Oncologist practicing medicine in Ventura, California. Dr. Hogan is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Malignant Mixed Mullerian Tumor, and Testicular Yolk Sac Tumor. Dr. Hogan is board certified in Gynecologic Oncology. Dr. Hogan is currently accepting new patients.

Frequently Asked Questions about Dr. Mukul R. Gupta

How do I make an appointment with Dr. Mukul R. Gupta?

You can book an appointment with Dr. Mukul R. Gupta by calling their office at 805-879-0670. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mukul R. Gupta a top-rated expert for Familial Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mukul R. Gupta is classified as an Advanced expert for Familial Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mukul R. Gupta specialize in?

While Dr. Mukul R. Gupta is a Oncology, they have specific expertise in Familial Pancreatic Cancer, Myelodysplastic Syndrome (MDS), and Urothelial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mukul R. Gupta participate in research or clinical trials?

Yes. Dr. Mukul R. Gupta has published 5 articles and abstracts on conditions like Familial Pancreatic Cancer. You can view a list of Dr. Mukul R. Gupta's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mukul R. Gupta accept my insurance?

Dr. Mukul R. Gupta accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 805-879-0670 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gupta's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 79 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile